Vaginal DNA Assay Shows Promise - Takeaways - MDSpire
From the Journals

Vaginal DNA Assay Shows Promise

A two-marker methylated DNA assay identified endometrial cancer with 96% sensitivity in self-collected vaginal fluid — but prospective validation is needed before it can reduce biopsies in routine care.

  • By

  • Kerri Miller

  • May 8, 2026

  • 14 min

Share

  • 1

    New assay detects endometrial cancer with 96% sensitivity.

  • 2

    Samples collected using unscented tampons.

  • 3

    Assay requires further validation for real-world use.

  • 4

    Limited performance for atypical endometrial hyperplasia (43% sensitivity).

  • 5

    Study involved 15 institutions.

  • 6

    Focus on improving diagnostic pathways for abnormal uterine bleeding.

  • 7

    Need for negative predictive value analysis emphasized.

Original Source(s)

Vaginal DNA Assay Shows Promise

  • by Kerri Miller

  • May 8, 2026

Related Content

Premenstrual Disorders Linked to Broad Psychiatric Risk

Swedish study finds two-way associations between premenstrual disorders and psychiatric conditions, with strongest links involving depression, anxiety, attention-deficit/hyperactivity disorder, bipolar disorder, and personality disorders.

31 Live Births Reported Following Uterus Transplant

Single-center series details maternal, obstetric, and neonatal outcomes among recipients with uterine-factor infertility

Cervical Cancer Trends Differ by Age

Recent declines among women younger than 35 years contrasted with rising long-term incidence among women aged 35 to 49 years in Puerto Rico